In response to newly identified, community-based HIV epidemics, the AETC NCRC has pulled together the following AETC Program and U.S. Centers for Dise...
Case-based training slides provide guidance for assessing atherosclerotic cardiovascular disease (ASCVD) risk in people with HIV.
Each year HRSA's HIV/AIDS Bureau sponsors a conference for Ryan White Program clinicians to learn about advances in care and treatment. The AETC Natio...
Immediate antiretroviral therapy (ART) means starting HIV treatment as soon as possible after the diagnosis of HIV infection, preferably on the first...
This digital glossary of HIV-related terms includes both lay and scientific descriptions and illustrations. Materials are in the public domain and may...
Training slides covering U.S. HHS treatment recommendations related to starting antiretroviral therapy (ART) in people with HIV infection. Topics incl...
The National HIV Curriculum (NHC) provides free, up-to-date content for clinicians to learn about HIV diagnosis, treatment, and prevention. The 37 les...
(Recorded on 08/09/2023)
Presenters provide significant findings and key updates from the 24th International AIDS Conference.
Kenn...
These training slides review current literature on the efficacy of long-acting anti-retroviral therapy, reasons to switch from oral to long-acting ART...
(Recorded on 03/11/2024)
This recorded webinar reviews the global epidemiology of pediatric HIV infection, describes efforts to prevent new child infec...
These slides follow a case study of a person with HIV, who presents with a rash caused by a fungal infection. Each slide provides a follow up on the t...
This presentation provides current guidelines for the use of antiretroviral therapy (ART) agents in adults and adolescents with HIV.
The HIV epidemic is an important public health priority. Transmissions continue to occur despite effective therapies that make HIV preventable and tre...
The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and deat...
In April 2019, the U.S. Food and Drug Administration approved a combination pill comprising the integrase inhibitor dolutegravir (DTG), 50 mg, and the NRTI lamivudine (3TC), 300 mg, for use as a complete ARV regimen for initial HIV treatment of patients. The approval specifies that DTG/3TC is intend...
